Top

Published in:

01-06-2010

Bone marrow-derived mesenchymal stem cells and the tumor microenvironment

Authors: Scott A. Bergfeld, Yves A. DeClerck

Published in: Cancer and Metastasis Reviews | Issue 2/2010

Abstract

Over the last decade, there has been a growing interest in the role of mesenchymal stem cells (MSC) in cancer progression. These cells have the potential to give rise to a variety of mesenchymal cells like osteoblasts, chondrocytes, adipocytes, fibroblasts, and muscle cells. In contrast to their hematopoetic counterparts, MSC are not as clearly defined, which makes the interpretation of their role in cancer progression more complex. However, the nature of the relationship between MSC and tumor cells appears dual. Primary and metastatic tumors attract MSC in their microenvironment where they become tumor-associated fibroblasts, affect tumor cell survival and angiogenesis, and have an immunomodulatory function, and vice versa in the bone marrow MSC attract tumor cells and contribute to a microenvironment that promotes osteolysis, tumor growth, survival, and drug resistance. Whether MSC are pro- or anti-tumorigenic is a subject of controversial reports that is in part explained by the complexity of their interaction with tumor cells and the large range of cytokines and growth factors they produce. The study of these interactions is a fertile ground of investigation that—as already demonstrated in the case of myeloma—should lead to novel therapeutic approaches in cancer. In this article, the biology and role of MSC in cancer is reviewed with a primary focus on bone marrow-derived MSC.

Prockop, D. J. (2009). Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Molecular Therapy, 17, 939–946.PubMedCrossRef

Caplan, A. I. (1994). The mesengenic process. Clinics in Plastic Surgery, 21, 429–435.PubMed

Valtieri, M., & Sorrentino, A. (2008). The mesenchymal stromal cell contribution to homeostasis. Journal of Cellular Physiology, 217, 296–300.PubMedCrossRef

Dennis, J. E., & Charbord, P. (2002). Origin and differentiation of human and murine stroma. Stem Cells, 20, 205–214.PubMedCrossRef

Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143–147.PubMedCrossRef

Civin, C. I., Trischmann, T., Kadan, N. S., Davis, J., Noga, S., Cohen, K., et al. (1996). Highly purified CD34-positive cells reconstitute hematopoiesis. Journal of Clinical Oncology, 14, 2224–2233.PubMed

Shi, S., & Gronthos, S. (2003). Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. Journal of Bone and Mineral Research, 18, 696–704.PubMedCrossRef

Wagner, W., & Ho, A. D. (2007). Mesenchymal stem cell preparations—comparing apples and oranges. Stem Cell Reviews and Reports, 3, 239–248.PubMedCrossRef

Vaananen, H. K. (2005). Mesenchymal stem cells. Annals of Medicine, 37, 469–479.PubMedCrossRef

10.

Friedenstein, A. J., Piatetzky-Shapiro, I. I., & Petrakova, K. V. (1966). Osteogenesis in transplants of bone marrow cells. Journal of Embryology and Experimental Morphology, 16, 381–390.PubMed

11.

Friedenstein, A. J., Chailakhyan, R. K., Latsinik, N. V., Panasyuk, A. F., & Keiliss-Borok, I. V. (1974). Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation, 17, 331–340.PubMedCrossRef

12.

Horwitz, E. M., Le Blanc, K., Dominici, M., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., et al. (2005). Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy, 7, 393–395.PubMedCrossRef

13.

Wagner, W., Feldmann, R. E., Jr., Seckinger, A., Maurer, M. H., Wein, F., Blake, J., et al. (2006). The heterogeneity of human mesenchymal stem cell preparations—evidence from simultaneous analysis of proteomes and transcriptomes. Experimental Hematology, 34, 536–548.PubMedCrossRef

14.

Lodie, T. A., Blickarz, C. E., Devarakonda, T. J., He, C., Dash, A. B., Clarke, J., et al. (2002). Systematic analysis of reportedly distinct populations of multipotent bone marrow-derived stem cells reveals a lack of distinction. Tissue Engineering, 8, 739–751.PubMedCrossRef

15.

Tropel, P., Noel, D., Platet, N., Legrand, P., Benabid, A. L., & Berger, F. (2004). Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow. Experimental Cell Research, 295, 395–406.PubMedCrossRef

16.

Colter, D. C., Sekiya, I., & Prockop, D. J. (2001). Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proceedings of the National Academy of Sciences of the United States of America, 98, 7841–7845.PubMedCrossRef

17.

Battula, V. L., Treml, S., Bareiss, P. M., Gieseke, F., Roelofs, H., de Zwart, P., et al. (2009). Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica, 94, 173–184.PubMedCrossRef

18.

Kaiser, S., Hackanson, B., Follo, M., Mehlhorn, A., Geiger, K., Ihorst, G., et al. (2007). BM cells giving rise to MSC in culture have a heterogeneous CD34 and CD45 phenotype. Cytotherapy, 9, 439–450.PubMedCrossRef

19.

Copland, I., Sharma, K., Lejeune, L., Eliopoulos, N., Stewart, D., Liu, P., et al. (2008). CD34 expression on murine marrow-derived mesenchymal stromal cells: impact on neovascularization. Experimental Hematology, 36, 93–103.PubMedCrossRef

20.

Conget, P. A., & Minguell, J. J. (1999). Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. Journal of Cellular Physiology, 181, 67–73.PubMedCrossRef

21.

Roche, S., Delorme, B., Oostendorp, R. A., Barbet, R., Caton, D., Noel, D., et al. (2009). Comparative proteomic analysis of human mesenchymal and embryonic stem cells: towards the definition of a mesenchymal stem cell proteomic signature. Proteomics, 9, 223–232.PubMedCrossRef

22.

Kemp, K. C., Hows, J., & Donaldson, C. (2005). Bone marrow-derived mesenchymal stem cells. Leukaemia & Lymphoma, 46, 1531–1544.CrossRef

23.

Simmons, P. J., & Torok-Storb, B. (1991). Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood, 78, 55–62.PubMed

24.

Jones, E., & McGonagle, D. (2008). Human bone marrow mesenchymal stem cells in vivo. Rheumatology (Oxford), 47, 126–131.CrossRef

25.

Rider, D. A., Nalathamby, T., Nurcombe, V., & Cool, S. M. (2007). Selection using the alpha-1 integrin (CD49a) enhances the multipotentiality of the mesenchymal stem cell population from heterogeneous bone marrow stromal cells. Journal of Molecular Histology, 38, 449–458.PubMedCrossRef

26.

Stewart, K., Monk, P., Walsh, S., Jefferiss, C. M., Letchford, J., & Beresford, J. N. (2003). STRO-1, HOP-26 (CD63), CD49a and SB-10 (CD166) as markers of primitive human marrow stromal cells and their more differentiated progeny: a comparative investigation in vitro. Cell and Tissue Research, 313, 281–290.PubMedCrossRef

27.

Prockop, D. J. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 276, 71–74.PubMedCrossRef

28.

Izadpanah, R., Trygg, C., Patel, B., Kriedt, C., Dufour, J., Gimble, J. M., et al. (2006). Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. Journal of Cellular Biochemistry, 99, 1285–1297.PubMedCrossRef

29.

Gang, E. J., Bosnakovski, D., Figueiredo, C. A., Visser, J. W., & Perlingeiro, R. C. (2007). SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood, 109, 1743–1751.PubMedCrossRef

30.

Mackay, A. M., Beck, S. C., Murphy, J. M., Barry, F. P., Chichester, C. O., & Pittenger, M. F. (1998). Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Engineering, 4, 415–428.PubMedCrossRef

31.

Denker, A. E., Haas, A. R., Nicoll, S. B., & Tuan, R. S. (1999). Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: I. Stimulation by bone morphogenetic protein-2 in high-density micromass cultures. Differentiation, 64, 67–76.PubMedCrossRef

32.

Goessler, U. R., Bieback, K., Bugert, P., Heller, T., Sadick, H., Hormann, K., et al. (2006). In vitro analysis of integrin expression during chondrogenic differentiation of mesenchymal stem cells and chondrocytes upon dedifferentiation in cell culture. International Journal of Molecular Medicine, 17, 301–307.PubMed

33.

Menicanin, D., Bartold, P. M., Zannettino, A. C., & Gronthos, S. (2009). Genomic profiling of mesenchymal stem cells. Stem Cell Reviews and Reports, 5, 36–50.PubMedCrossRef

34.

Rich, J. T., Rosova, I., Nolta, J. A., Myckatyn, T. M., Sandell, L. J., & McAlinden, A. (2008). Upregulation of Runx2 and Osterix during in vitro chondrogenesis of human adipose-derived stromal cells. Biochemical and Biophysical Research Communications, 372, 230–235.PubMedCrossRef

35.

Sekiya, I., Larson, B. L., Vuoristo, J. T., Cui, J. G., & Prockop, D. J. (2004). Adipogenic differentiation of human adult stem cells from bone marrow stroma (MSCs). Journal of Bone and Mineral Research, 19, 256–264.PubMedCrossRef

36.

McBeath, R., Pirone, D. M., Nelson, C. M., Bhadriraju, K., & Chen, C. S. (2004). Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Developmental Cell, 6, 483–495.PubMedCrossRef

37.

Schilling, T., Noth, U., Klein-Hitpass, L., Jakob, F., & Schutze, N. (2007). Plasticity in adipogenesis and osteogenesis of human mesenchymal stem cells. Molecular and Cellular Endocrinology, 271, 1–17.PubMedCrossRef

38.

Akavia, U. D., Veinblat, O., & Benayahu, D. (2008). Comparing the transcriptional profile of mesenchymal cells to cardiac and skeletal muscle cells. Journal of Cellular Physiology, 216, 663–672.PubMedCrossRef

39.

Park, J. S., Chu, J. S., Cheng, C., Chen, F., Chen, D., & Li, S. (2004). Differential effects of equiaxial and uniaxial strain on mesenchymal stem cells. Biotechnology and Bioengineering, 88, 359–368.PubMedCrossRef

40.

Ball, S. G., Shuttleworth, C. A., & Kielty, C. M. (2007). Platelet-derived growth factor receptor-alpha is a key determinant of smooth muscle alpha-actin filaments in bone marrow-derived mesenchymal stem cells. International Journal of Biochemistry and Cell Biology, 39, 379–391.PubMedCrossRef

41.

Wang, E. A., Israel, D. I., Kelly, S., & Luxenberg, D. P. (1993). Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3 T3 cells. Growth Factors, 9, 57–71.PubMedCrossRef

42.

Chen, D., Ji, X., Harris, M. A., Feng, J. Q., Karsenty, G., Celeste, A. J., et al. (1998). Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages. Developments in Cell Biology, 142, 295–305.

43.

Liu, Z., Tang, Y., Qiu, T., Cao, X., & Clemens, T. L. (2006). A dishevelled-1/Smad1 interaction couples WNT and bone morphogenetic protein signaling pathways in uncommitted bone marrow stromal cells. Journal of Biological Chemistry, 281, 17156–17163.PubMedCrossRef

44.

Locklin, R. M., Oreffo, R. O., & Triffitt, J. T. (1999). Effects of TGFbeta and bFGF on the differentiation of human bone marrow stromal fibroblasts. Cell Biology International, 23, 185–194.PubMedCrossRef

45.

Jian, H., Shen, X., Liu, I., Semenov, M., He, X., & Wang, X. F. (2006). Smad3-dependent nuclear translocation of beta-catenin is required for TGF-beta1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes and Development, 20, 666–674.PubMedCrossRef

46.

Maeda, S., Hayashi, M., Komiya, S., Imamura, T., & Miyazono, K. (2004). Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO Journal, 23, 552–563.PubMedCrossRef

47.

Roelen, B. A., & Dijke, P. (2003). Controlling mesenchymal stem cell differentiation by TGFBeta family members. Journal of Orthopaedic Science, 8, 740–748.PubMedCrossRef

48.

Gazit, D., Zilberman, Y., Turgeman, G., Zhou, S., & Kahn, A. (1999). Recombinant TGF-beta1 stimulates bone marrow osteoprogenitor cell activity and bone matrix synthesis in osteopenic, old male mice. Journal of Cellular Biochemistry, 73, 379–389.PubMedCrossRef

49.

Walsh, S., Jefferiss, C., Stewart, K., & Beresford, J. N. (2003). TGFbeta1 limits the expansion of the osteoprogenitor fraction in cultures of human bone marrow stromal cells. Cell and Tissue Research, 311, 187–198.PubMed

50.

Ling, L., Nurcombe, V., & Cool, S. M. (2009). Wnt signaling controls the fate of mesenchymal stem cells. Gene, 433, 1–7.PubMedCrossRef

51.

Boland, G. M., Perkins, G., Hall, D. J., & Tuan, R. S. (2004). Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. Journal of Cellular Biochemistry, 93, 1210–1230.PubMedCrossRef

52.

Baksh, D., Boland, G. M., & Tuan, R. S. (2007). Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. Journal of Cellular Biochemistry, 101, 1109–1124.PubMedCrossRef

53.

De Boer, J., Wang, H. J., & Van Blitterswijk, C. (2004). Effects of Wnt signaling on proliferation and differentiation of human mesenchymal stem cells. Tissue Engineering, 10, 393–401.PubMedCrossRef

54.

Eijken, M., Meijer, I. M., Westbroek, I., Koedam, M., Chiba, H., Uitterlinden, A. G., et al. (2008). Wnt signaling acts and is regulated in a human osteoblast differentiation dependent manner. Journal of Cellular Biochemistry, 104, 568–579.PubMedCrossRef

55.

Lee, H., Herrmann, A., Deng, J. H., Kujawski, M., Niu, G., Li, Z., et al. (2009). Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell, 15, 283–293.PubMedCrossRef

56.

Hartmann, C., & Tabin, C. J. (2000). Dual roles of Wnt signaling during chondrogenesis in the chicken limb. Development, 127, 3141–3159.PubMed

57.

Bergwitz, C., Wendlandt, T., Kispert, A., & Brabant, G. (2001). Wnts differentially regulate colony growth and differentiation of chondrogenic rat calvaria cells. Biochimica et Biophysica Acta, 1538, 129–140.PubMed

58.

Tuli, R., Tuli, S., Nandi, S., Huang, X., Manner, P. A., Hozack, W. J., et al. (2003). Transforming growth factor-beta-mediated chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and mitogen-activated protein kinase and Wnt signaling cross-talk. Journal of Biological Chemistry, 278, 41227–41236.PubMedCrossRef

59.

Ridgeway, A. G., Petropoulos, H., Wilton, S., & Skerjanc, I. S. (2000). Wnt signaling regulates the function of MyoD and myogenin. Journal of Biological Chemistry, 275, 32398–32405.PubMedCrossRef

60.

Suzawa, M., Takada, I., Yanagisawa, J., Ohtake, F., Ogawa, S., Yamauchi, T., et al. (2003). Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. Nature Cell Biology, 5, 224–230.PubMedCrossRef

61.

Phinney, D. G., & Prockop, D. J. (2007). Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views. Stem Cells, 25, 2896–2902.PubMedCrossRef

62.

Reyes, M., Lund, T., Lenvik, T., Aguiar, D., Koodie, L., & Verfaillie, C. M. (2001). Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood, 98, 2615–2625.PubMedCrossRef

63.

Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-Gonzalez, X. R., et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature, 418, 41–49.PubMedCrossRef

64.

Shiota, M., Heike, T., Haruyama, M., Baba, S., Tsuchiya, A., Fujino, H., et al. (2007). Isolation and characterization of bone marrow-derived mesenchymal progenitor cells with myogenic and neuronal properties. Experimental Cell Research, 313, 1008–1023.PubMedCrossRef

65.

Hall, B., Andreeff, M., & Marini, F. (2007). The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handbook of Experimental Pharmacology, 263-283.

66.

Wu, X., Hu, J., Zhou, L., Mao, Y., Yang, B., Gao, L., et al. (2008). In vivo tracking of superparamagnetic iron oxide nanoparticle-labeled mesenchymal stem cell tropism to malignant gliomas using magnetic resonance imaging. Laboratory investigation. Journal of Neurosurgery, 108, 320–329.PubMedCrossRef

67.

Hung, S. C., Deng, W. P., Yang, W. K., Liu, R. S., Lee, C. C., Su, T. C., et al. (2005). Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clinical Cancer Research, 11, 7749–7756.PubMedCrossRef

68.

Kidd, S., Spaeth, E., Dembinski, J. L., Dietrich, M., Watson, K., Klopp, A., et al. (2009). Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells, 27, 2614–2623.PubMedCrossRef

69.

Ishii, G., Sangai, T., Oda, T., Aoyagi, Y., Hasebe, T., Kanomata, N., et al. (2003). Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochemical and Biophysical Research Communications, 309, 232–240.PubMedCrossRef

70.

Direkze, N. C., Hodivala-Dilke, K., Jeffery, R., Hunt, T., Poulsom, R., Oukrif, D., et al. (2004). Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Research, 64, 8492–8495.PubMedCrossRef

71.

Schichor, C., Birnbaum, T., Etminan, N., Schnell, O., Grau, S., Miebach, S., et al. (2006). Vascular endothelial growth factor a contributes to glioma-induced migration of human marrow stromal cells (hMSC). Experimental Neurology, 199, 301–310.PubMedCrossRef

72.

Birnbaum, T., Roider, J., Schankin, C. J., Padovan, C. S., Schichor, C., Goldbrunner, R., et al. (2007). Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. Journal of Neuro-Oncology, 83, 241–247.PubMedCrossRef

73.

Feng, B., & Chen, L. (2009). Review of mesenchymal stem cells and tumors: executioner or coconspirator? Cancer Biotherapy & Radiopharmaceuticals, 24, 717–721.CrossRef

74.

Spaeth, E., Klopp, A., Dembinski, J., Andreeff, M., & Marini, F. (2008). Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Therapy, 15, 730–738.PubMedCrossRef

75.

Dwyer, R. M., Potter-Beirne, S. M., Harrington, K. A., Lowery, A. J., Hennessy, E., Murphy, J. M., et al. (2007). Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clinical Cancer Research, 13, 5020–5027.PubMedCrossRef

76.

Xu, W. T., Bian, Z. Y., Fan, Q. M., Li, G., & Tang, T. T. (2009). Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Letters, 281, 32–41.PubMedCrossRef

77.

Hara, M., Murakami, T., & Kobayashi, E. (2008). In vivo bioimaging using photogenic rats: fate of injected bone marrow-derived mesenchymal stromal cells. Journal of Autoimmunity, 30, 163–171.PubMedCrossRef

78.

Wynn, R. F., Hart, C. A., Corradi-Perini, C., O'Neill, L., Evans, C. A., Wraith, J. E., et al. (2004). A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood, 104, 2643–2645.PubMedCrossRef

79.

Gutova, M., Najbauer, J., Frank, R. T., Kendall, S. E., Gevorgyan, A., Metz, M. Z., et al. (2008). Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells, 26, 1406–1413.PubMedCrossRef

80.

Ho, I. A., Chan, K. Y., Ng, W. H., Guo, C. M., Hui, K. M., Cheang, P., et al. (2009). Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells, 27, 1366–1375.PubMedCrossRef

81.

Dvorak, H. F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine, 315, 1650–1659.PubMed

82.

Kidd, S., Spaeth, E., Klopp, A., Andreeff, M., Hall, B., & Marini, F. C. (2008). The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy, 10, 657–667.PubMedCrossRef

83.

Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., et al. (2009). Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE, 4, e4992.PubMedCrossRef

84.

Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., et al. (2008). Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Research, 68, 4331–4339.PubMedCrossRef

85.

Coffelt, S. B., Marini, F. C., Watson, K., Zwezdaryk, K. J., Dembinski, J. L., LaMarca, H. L., et al. (2009). The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proceedings of the National Academy of Sciences of the United States of America, 106, 3806–3811.PubMedCrossRef

86.

Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., et al. (2006). Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. Journal of Experimental Medicine, 203, 1235–1247.PubMedCrossRef

87.

Soria, G., & Ben Baruch, A. (2008). The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Letters, 267, 271–285.PubMedCrossRef

88.

Zhu, W., Xu, W., Jiang, R., Qian, H., Chen, M., Hu, J., et al. (2006). Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Experimental and Molecular Pathology, 80, 267–274.PubMedCrossRef

89.

Wang, H., Cao, F., De, A., Cao, Y., Contag, C., Gambhir, S. S., et al. (2009). Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells, 27, 1548–1558.PubMedCrossRef

90.

Galie, M., Konstantinidou, G., Peroni, D., Scambi, I., Marchini, C., Lisi, V., et al. (2008). Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene, 27, 2542–2551.PubMedCrossRef

91.

Tabe, Y., Konopleva, M., Munsell, M. F., Marini, F. C., Zompetta, C., McQueen, T., et al. (2004). PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood, 103, 1815–1822.PubMedCrossRef

92.

Lanza, C., Morando, S., Voci, A., Canesi, L., Principato, M. C., Serpero, L. D., et al. (2009). Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. Journal of Neurochemistry, 110, 1674–1684.PubMedCrossRef

93.

Sun, B., Roh, K. H., Park, J. R., Lee, S. R., Park, S. B., Jung, J. W., et al. (2009). Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy, 11(289–98), 1.

94.

Lu, Y. R., Yuan, Y., Wang, X. J., Wei, L. L., Chen, Y. N., Cong, C., et al. (2008). The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biology & Therapy, 7, 245–251.

95.

Wang, Y., Crisostomo, P. R., Wang, M., Markel, T. A., Novotny, N. M., & Meldrum, D. R. (2008). TGF-alpha increases human mesenchymal stem cell-secreted VEGF by MEK- and PI3-K- but not JNK- or ERK-dependent mechanisms. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 295, R1115–R1123.PubMed

96.

Lee, D. C., Fenton, S. E., Berkowitz, E. A., & Hissong, M. A. (1995). Transforming growth factor alpha: expression, regulation, and biological activities. Pharmacological Reviews, 47, 51–85.PubMed

97.

Beckermann, B. M., Kallifatidis, G., Groth, A., Frommhold, D., Apel, A., Mattern, J., et al. (2008). VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. British Journal of Cancer, 99, 622–631.PubMedCrossRef

98.

Rajantie, I., Ilmonen, M., Alminaite, A., Ozerdem, U., Alitalo, K., & Salven, P. (2004). Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood, 104, 2084–2086.PubMedCrossRef

99.

Al Khaldi, A., Eliopoulos, N., Martineau, D., Lejeune, L., Lachapelle, K., & Galipeau, J. (2003). Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Therapy, 10, 621–629.PubMedCrossRef

100.

Otsu, K., Das, S., Houser, S. D., Quadri, S. K., Bhattacharya, S., & Bhattacharya, J. (2009). Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood, 113, 4197–4205.PubMedCrossRef

101.

Sotiropoulou, P. A., & Papamichail, M. (2007). Immune properties of mesenchymal stem cells. Methods in Molecular Biology, 407, 225–243.PubMedCrossRef

102.

Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., et al. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99, 3838–3843.PubMedCrossRef

103.

Plumas, J., Chaperot, L., Richard, M. J., Molens, J. P., Bensa, J. C., & Favrot, M. C. (2005). Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia, 19, 1597–1604.PubMedCrossRef

104.

Rutella, S., Danese, S., & Leone, G. (2006). Tolerogenic dendritic cells: cytokine modulation comes of age. Blood, 108, 1435–1440.PubMedCrossRef

105.

Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., et al. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood, 107, 367–372.PubMedCrossRef

106.

Prevosto, C., Zancolli, M., Canevali, P., Zocchi, M. R., & Poggi, A. (2007). Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell–lymphocyte interaction. Haematologica, 92, 881–888.PubMedCrossRef

107.

Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., et al. (2003). Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood, 102, 3837–3844.PubMedCrossRef

108.

Nauta, A. J., & Fibbe, W. E. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood, 110, 3499–3506.PubMedCrossRef

109.

Koc, O. N., Gerson, S. L., Cooper, B. W., Dyhouse, S. M., Haynesworth, S. E., Caplan, A. I., et al. (2000). Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. Journal of Clinical Oncology, 18, 307–316.PubMed

110.

Lazarus, H. M., Koc, O. N., Devine, S. M., Curtin, P., Maziarz, R. T., Holland, H. K., et al. (2005). Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biology of Blood and Marrow Transplantation, 11, 389–398.PubMedCrossRef

111.

Ning, H., Yang, F., Jiang, M., Hu, L., Feng, K., Zhang, J., et al. (2008). The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia, 22, 593–599.PubMedCrossRef

112.

Loebinger, M. R., Kyrtatos, P. G., Turmaine, M., Price, A. N., Pankhurst, Q., Lythgoe, M. F., et al. (2009). Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Research, 69, 8862–8867.PubMedCrossRef

113.

Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., et al. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449, 557–563.PubMedCrossRef

114.

Burger, J. A., & Kipps, T. J. (2002). Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leukaemia & Lymphoma, 43, 461–466.CrossRef

115.

Molloy, A. P., Martin, F. T., Dwyer, R. M., Griffin, T. P., Murphy, M., Barry, F. P., et al. (2009). Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. International Journal of Cancer, 124, 326–332.CrossRef

116.

Urashima, M., Chen, B. P., Chen, S., Pinkus, G. S., Bronson, R. T., Dedera, D. A., et al. (1997). The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood, 90, 754–765.PubMed

117.

Cook, G., Dumbar, M., & Franklin, I. M. (1997). The role of adhesion molecules in multiple myeloma. Acta Haematologica, 97, 81–89.PubMedCrossRef

118.

Uchiyama, H., Barut, B. A., Chauhan, D., Cannistra, S. A., & Anderson, K. C. (1992). Characterization of adhesion molecules on human myeloma cell lines. Blood, 80, 2306–2314.PubMed

119.

Faid, L., Van, R. I., De Waele, M., Facon, T., Schots, R., Lacor, P., et al. (1996). Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma. European Journal of Haematology, 57, 349–358.PubMedCrossRef

120.

Thomas, X., Anglaret, B., Magaud, J. P., Epstein, J., & Archimbaud, E. (1998). Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma. Leukaemia & Lymphoma, 32, 107–119.

121.

Michigami, T., Shimizu, N., Williams, P. J., Niewolna, M., Dallas, S. L., Mundy, G. R., et al. (2000). Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood, 96, 1953–1960.PubMed

122.

Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., & Dalton, W. S. (1999). Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93, 1658–1667.PubMed

123.

Shain, K. H., Yarde, D. N., Meads, M. B., Huang, M., Jove, R., Hazlehurst, L. A., et al. (2009). Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Research, 69, 1009–1015.PubMedCrossRef

124.

Hoang, B., Zhu, L., Shi, Y., Frost, P., Yan, H., Sharma, S., et al. (2006). Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood, 107, 4484–4490.PubMedCrossRef

125.

Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007). Neuroblastoma. Lancet, 369, 2106–2120.PubMedCrossRef

126.

Dubois, S. G., Kalika, Y., Lukens, J. N., Brodeur, G. M., Seeger, R. C., Atkinson, J. B., et al. (1999). Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. Journal of Pediatric Hematology/Oncology, 21, 181–189.PubMedCrossRef

127.

Sohara, Y., Shimada, H., Minkin, C., Erdreich-Epstein, A., Nolta, J. A., & DeClerck, Y. A. (2005). Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Research, 65, 1129–1135.PubMedCrossRef

128.

Ara, T., Song, L., Shimada, H., Keshelava, N., Russell, H. V., Metelitsa, L. S., et al. (2009). Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Research, 69, 329–337.PubMedCrossRef

129.

Fukaya, Y., Shimada, H., Wang, L. C., Zandi, E., & DeClerck, Y. A. (2008). Identification of Gal-3 binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. Journal of Biological Chemistry, 283, 18573–18581.PubMedCrossRef

130.

Kakonen, S. M., Selander, K. S., Chirgwin, J. M., Yin, J. J., Burns, S., Rankin, W. A., et al. (2002). Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. Journal of Biological Chemistry, 277, 24571–24578.PubMedCrossRef

131.

Guise, T. A. (2000). Molecular mechanisms of osteolytic bone metastases. Cancer, 88, 2892–2898.PubMedCrossRef

132.

Brocke-Heidrich, K., Kretzschmar, A. K., Pfeifer, G., Henze, C., Loffler, D., Koczan, D., et al. (2004). Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood, 103, 242–251.PubMedCrossRef

133.

Aggarwal, B. B., Sethi, G., Ahn, K. S., Sandur, S. K., Pandey, M. K., Kunnumakkara, A. B., et al. (2006). Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Annals of the New York Academy of Sciences, 1091, 151–169.PubMedCrossRef

134.

Yamagiwa, Y., Marienfeld, C., Meng, F., Holcik, M., & Patel, T. (2004). Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival. Cancer Research, 64, 1293–1298.PubMedCrossRef

135.

Lee, G., & Piquette-Miller, M. (2001). Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Canadian Journal of Physiology and Pharmacology, 79, 876–884.PubMedCrossRef

136.

Dreuw, A., Hermanns, H. M., Heise, R., Joussen, S., Rodriguez, F., Marquardt, Y., et al. (2005). Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts. Journal of Investigative Dermatology, 124, 28–37.PubMedCrossRef

137.

Efferth, T., Fabry, U., & Osieka, R. (2002). Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells. Anticancer Research, 22, 231–234.PubMed

138.

Pu, Y. S., Hour, T. C., Chuang, S. E., Cheng, A. L., Lai, M. K., & Kuo, M. L. (2004). Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate, 60, 120–129.PubMedCrossRef

139.

Ishikawa, F., Yoshida, S., Saito, Y., Hijikata, A., Kitamura, H., Tanaka, S., et al. (2007). Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nature Biotechnology, 25, 1315–1321.PubMedCrossRef

140.

De Toni, F., Racaud-Sultan, C., Chicanne, G., Mas, V. M., Cariven, C., Mesange, F., et al. (2006). A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene, 25, 3113–3122.PubMedCrossRef

141.

Arthur, A., Zannettino, A., & Gronthos, S. (2009). The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. Journal of Cellular Physiology, 218, 237–245.PubMedCrossRef

142.

Hare, J. M., & Chaparro, S. V. (2008). Cardiac regeneration and stem cell therapy. Current Opinion in Organ Transplantion, 13, 536–542.CrossRef

143.

Fritz, V., & Jorgensen, C. (2008). Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Current Stem Cell Research & Therapy, 3, 32–42.CrossRef

144.

Hall, B., Dembinski, J., Sasser, A. K., Studeny, M., Andreeff, M., & Marini, F. (2007). Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. International Journal of Hematology, 86, 8–16.PubMedCrossRef

145.

Sasportas, L. S., Kasmieh, R., Wakimoto, H., Hingtgen, S., van de Water, J. A., Mohapatra, G., et al. (2009). Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America, 106, 4822–4827.PubMedCrossRef

146.

Cavarretta, I. T., Altanerova, V., Matuskova, M., Kucerova, L., Culig, Z., & Altaner, C. (2010). Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Molecular Therapy, 18, 223–231.PubMedCrossRef

147.

Nakamizo, A., Marini, F., Amano, T., Khan, A., Studeny, M., Gumin, J., et al. (2005). Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Research, 65, 3307–3318.PubMed

148.

Nishimoto, N., & Kishimoto, T. (2006). Interleukin 6: from bench to bedside. Nature Clinical Practice Rheumatology, 2, 619–626.PubMedCrossRef

149.

Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z., et al. (2009). A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15, 7144–7152.PubMedCrossRef

Title: Bone marrow-derived mesenchymal stem cells and the tumor microenvironment
Authors: Scott A. Bergfeld
Yves A. DeClerck
Publication date: 01-06-2010
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9222-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Inflammation-mediated promotion of invasion and metastasis

Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity

Senescent cells as a source of inflammatory factors for tumor progression

Why not treat human cancer with interleukin-1 blockade?

TGFβ and cancer metastasis: an inflammation link

Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer